What compounds target MERTK?

BiohacksAI has identified 44 compounds that interact with MERTK (MER proto-oncogene, tyrosine kinase). Top compounds include: paclitaxel, erlotinib, alvocidib, foretinib, tozasertib. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is MERTK (MER proto-oncogene, tyrosine)?

MERTK is MER proto-oncogene, tyrosine kinase. It is a molecular target for 44 compounds documented in PubMed bioassay data. UniProt ID: Q12866. NCBI Gene ID: 10461.

MERTK

MOLECULAR TARGET

MER proto-oncogene, tyrosine kinase

UniProt: Q12866 NCBI Gene: 1046144 compounds

MERTK (MER proto-oncogene, tyrosine kinase) is targeted by 44 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting MERTK

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	paclitaxel	7.17	1301
2	erlotinib	5.55	256
3	alvocidib	4.52	91
4	foretinib	4.34	76
5	tozasertib	4.33	75
6	vandetanib	4.30	73
7	bosutinib	4.08	58
8	doramapimod	4.06	57
9	bi 2536	4.01	54
10	quizartinib	3.99	53
11	midostaurin	3.85	46
12	pazopanib	3.69	39
13	neratinib	3.66	38
14	nintedanib	3.61	36
15	pelitinib	3.50	32
16	tae 684	3.43	30
17	fedratinib	3.40	29
18	bms 777607	3.37	28
19	linifanib	3.33	27
20	mln 8054	3.33	27
21	tandutinib	3.22	24
22	dovitinib	3.09	21
23	jnj 7706621	3.09	21
24	at 9283	3.09	21
25	lestaurtinib	3.04	20
26	filgotinib	3.04	20
27	r 406	2.83	16
28	k 252a	2.83	16
29	cediranib	2.83	16
30	pha 665752	2.71	14
31	kw 2449	2.64	13
32	bemcentinib	2.64	13
33	ast 487	2.56	12
34	merestinib	2.48	11
35	gsk 461364	2.40	10
36	bms 754807	2.30	9
37	berzosertib	2.30	9
38	su 014813	2.20	8
39	rebastinib	2.20	8
40	mk 2461	2.08	7
41	itacitinib	1.95	6
42	Sorafenib	1.61	4
43	Axitinib	0.69	1
44	Crizotinib	0.69	1

About MERTK as a Drug Target

MERTK (MER proto-oncogene, tyrosine kinase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 44 compounds with documented MERTK interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

MERTK inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.